Dr. Reddy’s to Acquire Mayne Pharma U.S. Generics Portfolio

Dr. Reddy’s Laboratories subsidiary plans to broaden its generic drug portfolio through the purchase of Australia-based Mayne Pharma’s U.S. generic prescription products.

The portfolio includes approximately 45 commercial products, four pipeline products and 40 approved non-marketed products.

Many of the products are focused on women’s health, including a hormonal vaginal ring and a birth control pill.

Mayne Pharma will receive an upfront payment of approximately $90 million and contingent payments of up to $15 million.